$ENTA - Covid oral drug is here to stay. PFE expects Paxlovid 2023 sales to be around 8b...that's with 2022 inventory dragging the sales... So I would think 325 is viable and worth more than zero. The concern I think is the regulatory pathway? From RBC: "the U.S. regulatory path currently emphasizes demonstration of outcomes benefits (hospitalization, mortality, etc.) and this would be difficult to show in the current environment, barring a major mutation."
Market Data 
Markets 
AI
